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Family history is the best characterized risk factor for prostate
cancer together with age and race (Dijkman and Debruyne, 1996).
In many families, aggregation of prostate cancer is caused by
autosomal dominantly inherited susceptibility genes with high
penetrance (Carter et al, 1992). One of these susceptibility genes
is located on chromosome 1q24–25 (Smith et al, 1996).
Epidemiological studies have shown that the risk of prostate
cancer is increased two- to threefold for male first-degree relatives
of men with prostate cancer. Many of them have indicated that the
risk may be higher for brothers than for sons of men with prostate
cancer (Hayes et al, 1995; Keetch et al, 1995; Monroe et al, 1995;
Narod et al, 1995; Whittemore et al, 1995; Lesko et al, 1996;
Schaid et al, 1998; Bratt et al, 1999). These findings led to the
hypothesis that prostate cancer susceptibility may be transmitted
by X-linked or recessive inheritance in some families (Monroe et
al, 1995), and recently a prostate cancer susceptibility gene was
located to the long arm of the X chromosome (Xu et al, 1998).
Another gene on the X chromosome which may be involved in
hereditary prostate cancer susceptibility is the androgen receptor
(AR) gene. Androgens are potent growth factors for the normal
prostatic gland and are considered as important promoting factors
for the development of prostatic adenocarcinoma (Hakimi et al,
1996). Circulating androgens diffuse into prostatic cells where
they bind to the AR. The androgen–AR complex is transferred to
the cell nucleus where it binds to DNA and influences the tran-
scription of numerous genes (the so-called transactivation function
of the AR). The N-terminal transactivation domain of the AR
contains several polymorphic amino acid repeats, the most vari-
able of which is a glutamine repeat. This glutamine repeat is
encoded by a CAG repeat in exon 1 of the AR gene. About 75% of
whites have between 19 and 25 repeats (Giovannucci et al, 1997).
There is an inverse linear relation between CAG repeat length and
AR transactivation function (Chamberlain et al, 1994; Kazemi-
Esfarjani et al, 1995; Tut et al, 1997), in the upper extreme end
(> 40 repeats) manifested as the rare Kennedy’s disease with
symptoms such as muscular atrophy, low virilization and subfer-
tility (La Spada et al, 1991). Prostatic cells with short CAG repeats
in the AR gene would consequently have increased sensitivity to
proliferative stimulation of androgens, and the conditions for
malignant growth would therefore be better (Hakimi et al, 1996).
Interestingly, the frequency distribution of AR CAG repeat length
in different races co-varies with prostate cancer incidence (Irvine
et al, 1995). African-American men, who have the highest inci-
dence of prostate cancer in the world, more frequently have short
CAG repeats than white and Asian-Americans (Irvine et al, 1995).
Further indications of a relationship between the number of CAG
repeats in the AR and prostate cancer risk were found in
case–control studies, in which AR genes with short repeats were
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more common among men with prostate cancer than among
controls (Giovannucci et al, 1997; Hakimi et al, 1997; Ingles et al,
1997).
We have previously reported on a population-based
case–control study of family history as a risk factor for prostate
cancer (Bratt et al, 1999). That study showed, in concordance with
most other case–control studies, a larger risk of prostate cancer for
brothers (relative risk 3.6) than for sons (relative risk 2.2) of men
with prostate cancer. This led us to consider the possibility of an
X-linked susceptibility for prostate cancer in this population. Short
CAG repeats in the AR was a possible candidate for such an
X-linked susceptibility, and we did therefore perform a
case–control study to test this hypothesis. We also investigated the
relations between CAG repeat length and tumour stage and grade,
age at diagnosis and response to endocrine therapy.
MATERIALS AND METHODS
Study population
Patients with a histopathological diagnosis of prostatic adenocarci-
noma were selected from participants in a study of family history
as a risk factor for prostate cancer (Bratt et al, 1999).
Their family history of prostate cancer was assessed with ques-
tionnaires. The diagnoses of relatives reported to have prostate
cancer were verified in the regional tumour registry. The present
study included 92 cases with a negative family history of prostate
cancer, referred to as sporadic cases in the following text, 68 cases
reporting a father (n = 27) or a brother (n = 41) with prostate
cancer (later referred to as familial cases), and 30 patients with a
pedigree consistent with autosomally dominant hereditary prostate
cancer (Carter et al, 1993). All 190 prostate cancer patients were
whites living in southern Sweden at the time of diagnosis. Age,
tumour stage (localized, locally advanced, or metastatic), WHO
tumour grade (low, intermediate, or high), and prostate-specific
antigen (PSA) level at the time of diagnosis were registered for all
cases. Tumour grade and stage had similar distributions in the
three groups, whereas age at diagnosis had not: the median age
was 71 years for sporadic cases (range 45–89 years), 69 years for
familial cases (range 47–83 years) and 65 years for hereditary
cases (range 44–78 years).
Ninety-one of the prostate cancer patients received endocrine
therapy: 78 were treated with gonadotropin-releasing hormone
analogues, 12 with bilateral orchidectomy, and one received
bicalutamide as monotherapy. No-one was treated with maximal
androgen blockade. The response to endocrine therapy was cate-
gorized as good, intermediate, or poor. The categories for patients
with skeletal metastases were defined as follows: good response
was defined as relief of symptoms with a duration of 2 years or
more; intermediate response as initial relief of symptoms followed
by a symptomatic progress after 1–2 years; and poor response as
symptomatic progress within 1 year from start of treatment. For
patients without skeletal metastases good response was defined as
normalization of PSA (< 4 ng ml–1), relief of symptoms and
absence of any kind of progress for more than 2 years; the
response was categorized as poor when PSA did not decrease
to normal or if the disease progressed biochemically (PSA
> 4 ng ml–1) or clinically within 1 year from start of therapy;
responses falling in-between these categories were considered as
intermediate. Follow-up sufficient to categorize the response to
endocrine therapy was available for 73 patients.
The control group for calculation of prostate cancer risk
consisted of 186 AR alleles from 93 white women without any
history of cancer, living in the same geographical area as the
prostate cancer patients.
Analysis of CAG repeat length in the AR gene
Genomic DNA from leukocytes was used as template in poly-
merase chain reaction (PCR) amplification of an approximately
150 bp region in exon 1 of the AR gene comprising the poly-
morphic CAG repeat. Primer sequences were GCGCGAAGT-
GATCCAGAA (forward) and GTTGCTGTTCCTCATCCA
(reverse) (Lubahn et al, 1989). The forward primer was labelled by
T4 polynucleotide kinase and 32P-ATP, and PCR products were
analysed by electrophoresis in denaturing 6% polyacrylamide
gels. Alternatively, PCR products were fluorescence labelled by a
TET-tagged forward primer and analysed in an ABI310 DNA
fragment analyser using POP4 polymer and Genescan software
(Perkin-Elmer). In either case, three different PCR products
containing a sequence verified number of CAG repeats (14, 21 and
31 repeats) were used as standards for calculation of the numbers
of repeats in our samples.
Statistics
Unconditional logistic regression was used to analyse the relation
between CAG repeat length and risk of prostate cancer. CAG
repeat length was analysed both as a discrete numerical variable
and categorized in tertiles. Hereditary prostate cancer is con-
sidered to be caused by germline mutations in specific dominant
susceptibility genes with high penetrance (Carter et al, 1993), and
the number of CAG repeats is therefore unlikely to contribute
significantly to prostate cancer risk in this group of patients.
Hence, the 30 cases with hereditary prostate cancer were excluded
in these analyses.
The relations between CAG repeat length and tumour stage,
tumour grade, and response to endocrine therapy were assessed
with one-way analysis of variance and logistic regression, whereas
the association between repeat length and age at diagnosis was
analysed with univariate and multivariate linear regression and by
calculating Pearson’s correlation coefficient. All significance tests
were two-tailed.
RESULTS
Mean CAG repeat length was 21.8 (range 15–31) for prostate
cancer cases and 21.7 (range 12–30) in the control group. Mean
repeat length was 22.1 for patients with sporadic prostate cancer,
22.3 for patients with a brother diagnosed with prostate cancer,
20.9 for patients whose father had prostate cancer and 21.0 for
patients with hereditary prostate cancer. The differences in repeat
length between these four groups were not statistically significant.
The study included samples from nine brother pairs with prostate
cancer. CAG repeat length was not significantly different for the
five brother pairs in which CAG repeat length was equal for both
brothers (mean 22.8), compared to the four brother pairs with
unequal repeat length (mean 20.7).
The distribution of CAG alleles was similar for cases and
controls (Figure 1). Logistic regression analysis showed no
significant association between CAG repeat length and risk of
prostate cancer, neither when CAG repeat length was categorized674 O Bratt et al
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in tertiles (data not shown), nor when it was analysed as a discrete
numerical variable. Odds ratios calculated for a decrement of one
CAG triplet were 0.97 (95% confidence interval (CI) 0.91–1.04,
P = 0.47) for non-hereditary prostate cancer, 1.01 (95% CI
0.93–1.10,  P = 0.75) for high-grade or high-stage non-hereditary
prostate cancer, and 1.08 (95% CI 0.97–1.20, P = 0.15) for non-
hereditary prostate cancer diagnosed before the age of 65 years.
The odds ratios were not higher when only cases with a family
history consistent with X-linked prostate cancer susceptibility
were included (data not shown).
Patients with high-grade tumours had shorter CAG repeats
(mean 21.0) than patients with low or intermediate grade tumours
(mean 22.0), but the difference was not statistically significant
(P = 0.07). The odds ratio for high-grade tumours was 1.13 per
each CAG triplet decrement (95% CI 0.99–1.29, P = 0.07). The
relation between CAG repeat length and tumour stage was similar:
patients with locally advanced or metastatic disease had shorter
CAG repeats (mean 21.4) than patients with localized disease
(mean 22.2, P = 0.07). The odds ratio for locally advanced or
metastatic disease was 1.09 (95% CI 0.99–1.21, P = 0.08).
CAG repeat length did significantly correlate with age at diag-
nosis of prostate cancer (correlation coefficient 0.16, P = 0.03).
Univariate regression analysis showed a significant linear relation
between CAG repeat length and age at diagnosis for sporadic and
familial cases (regression coefficient 0.48, P = 0.03), but not for
hereditary cases (regression coefficient 0.15, P = 0.8). The relation
between CAG repeat length and age was similar for familial cases
having a father with prostate cancer and for those having a brother
with prostate cancer. The regression coefficient and P-value did
not change when a multiple regression analysis was performed
adding tumour grade and stage as co-variates. Mean CAG repeat
length in different age groups and mean age at diagnosis for cases
grouped in tertiles of CAG repeat length are shown in Table 1.
We also found a significant association between CAG repeat
length and response to endocrine therapy (variance analysis,
P = 0.04). The 45 patients with good response had longer CAG
repeats (mean 22.7) than the 11 with intermediate response (mean
20.8) and the 17 with poor response (mean 21.1). In univariate
logistic regression the odds ratio for good response was 1.26 (95%
CI 1.05–1.52, P = 0.01) per each CAG triplet increment. When
adjusting for tumour grade, tumour stage and PSA level at initia-
tion of therapy in a multiple backward logistic regression model,
CAG repeat length remained a significant independent predictor of
response. This means that a good response to endocrine therapy
was four times more likely for patients with 25 repeats than for
patients with 19 repeats (a 6-CAG triplets increment, 1.266 = 4.0),
which represents the upper and lower limits of the 75th percentile
of the distribution of CAG repeat length in a white population
(Giovannucci, 1997). That tumour stage was not significantly
associated with response to endocrine therapy in multivariate
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Figure 1 Frequency distribution of CAG repeat length in the AR gene from 160 men with non-hereditary prostate cancer and 186 AR gene alleles from the
population
Table 1 Relation between CAG repeat length in the AR gene and age at
diagnosis of non-hereditary prostate cancer
Age at diagnosis Mean CAG repeats Cases
(years) (No.) (No.)
<65 21.0 44
65–75 22.2 79
>75 22.4 37
CAG repeats Mean age at diagnosis Cases
(No.) (years) (No.)
15–20 67.3 52
21–23 68.7 62
24–31 70.9 46
Table 2 Odds ratios for good response to endocrine therapy in 73 patients
with prostate cancer, calculated with multiple backwards logistic regression
Variable Odds ratio 95% CI P-value
CAG repeat length 1.25 1.00–1.57 0.05
Tumour grade 0.38 0.13–0.84 0.02
Log PSA 0.34 0.12–0.94 0.04
Tumour stage 0.69 0.23–2.09 0.51
CAG repeat length was analysed as a discrete numerical variable and odds
ratios were calculated for increments of one CAG triplet. Tumour stage was
excluded from the final equation since it was not significantly related to
response. CI – confidence interval, Log PSA – the logarithm of the pre-
therapeutic level of prostatic-specific antigen.analysis is explained by that the categories for response were
different for patients with non-metastatic disease than for patients
with metastasis.
DISCUSSION
The present study gave no evidence of an association between
short CAG repeats in exon 1 of the AR gene and increased risk of
prostate cancer. The frequency distribution of CAG repeat length
was strikingly similar for cases and controls, with no CAG repeat
interval more common among cases than among controls
(Figure 1). We did, however, in accordance with Hardy et al
(1996), find a significant correlation between CAG repeat length
and age at diagnosis of sporadic and familial prostate cancer.
Assuming that prostatic cells with short glutamine repeats in the
AR are more sensitive to circulating androgens (Chamberlain et al,
1994; Kazemi-Esfarjani et al, 1995; Tut et al, 1997), a correlation
between short CAG repeats in the AR gene and low age at
diagnosis of prostate cancer is to be expected: prostatic adenocar-
cinoma cells with short CAG repeats would be more proliferative
and therefore progress faster from microscopic lesions to clinically
overt tumours.
If CAG repeat length correlates with age at onset of prostate
cancer, but not with risk of prostate cancer per se, age at onset is a
confounder in case–control studies of CAG repeat length and
prostate cancer risk. If predominantly early onset cases are
included, data are not valid for direct calculation of prostate cancer
risk, which would be over-estimated if the effect of age at diag-
nosis of cases is not adjusted for. Two of four previous case–
control studies included mainly prostate cancer cases diagnosed
before the age of 65 (Ingles et al, 1997; Stanford et al, 1997),
whereas age at diagnosis was not reported in the other two studies
(Giovannucci et al, 1997; Hakimi et al, 1997). Our study included
patients of all ages, but when the analysis was restricted to cases
diagnosed before the age of 65, the odds ratio for prostate cancer
increased to 1.08 per each CAG triplet decrement. Consequently,
the odds ratio was 1.6 (1.086) per six CAG triplets decrement,
which is in the same range as previously reported for six CAG
decrements (Giovannucci et al, 1997).
We found no association between CAG repeat length and age at
diagnosis for patients with hereditary prostate cancer, which may
reflect a pathogenetical difference between prostatic tumours
caused by germline mutations in specific prostate cancer suscepti-
bility genes and non-hereditary prostate cancer.
Many epidemiological studies have shown a higher risk of
prostate cancer for brothers than for sons of men with prostate
cancer (Hayes et al, 1995; Keetch et al, 1995; Monroe et al, 1995;
Narod et al, 1995; Whittemore et al, 1995; Lesko et al, 1996;
Schaid et al, 1998; Bratt et al, 1999). These findings led to the
hypothesis that prostate cancer susceptibility may be X-linked in
some families (Monroe et al, 1995), and were the incitement for
the present study. However, our results were totally negative as
regards an association between CAG repeat length and prostate
cancer risk. Information bias and detection bias likely contribute to
the above mentioned findings in the epidemiological studies (Bratt
et al, 1999), but recently a prostate cancer susceptibility gene was
indeed mapped to the long arm of the X chromosome (Xu et al,
1998). This gene, named HPCX, is most likely a more important
cause of X-linked inheritance of prostate cancer, than is CAG
repeat length polymorphism in the AR gene. There are, however,
other polymorphisms in the AR gene that might be of importance
for prostate cancer pathogenesis (Irvine et al, 1995; Ross et al,
1998).
The cause of the association between long CAG repeats and
good response to endocrine therapy is obscure. Circulating andro-
genic hormones stimulate proliferation of most prostatic adenocar-
cinomas, and androgen withdrawal is standard therapy for patients
with advanced prostate cancer. As a rule, the disease will eventu-
ally become androgen-independent and escape therapeutic control,
though the duration of response to androgen withdrawal therapy
varies widely. The effects of androgens on prostatic carcinoma
cells are mediated by the AR, and inter-individual differences in
AR activity may thus contribute to the variable clinical response to
endocrine therapy.
Loss of hormonal dependence is commonly caused by develop-
ment of less differentiated tumour clones through accumulative
genetic abnormalities occurring mainly during cell division
(Rinker-Schaeffer et al, 1994). Assuming that prostate cancer cells
with short CAG repeats in the AR divide more rapidly, they would
be more likely to give origin to androgen-independent cell clones
early in tumour progression. If this hypothesis were true, one
would expect an association between short CAG repeats and
high tumour grade. Such an association was indeed found by
Giovannucci et al (1997), and there was a trend in that direction in
the present study. High-grade tumours are somewhat more
common in men with early onset prostate cancer (Grönberg et al,
1994). Short CAG repeats might be a common risk factor for early
onset disease and high-grade tumours and could thus contribute to
this relation, but other explanations are possible (Bratt et al, 1998).
Hardy and co-workers (Hardy et al, 1996) found no relation
between CAG repeat length and response to endocrine therapy.
Their classification of response and statistical work-up were
entirely different from the evaluation in our study and comparisons
between their study and ours are therefore difficult to make. The
number of patients in our study was small and the time of follow-
up was short, and further studies are needed before any conclu-
sions can be made regarding a possible causative relation between
CAG repeat length and response to endocrine therapy.
We conclude that in the studied population of whites in southern
Sweden, short CAG repeats in the AR gene correlate with younger
age at diagnosis of sporadic and familial prostate cancer, but not
with increased risk of prostate cancer in general. An association
between long CAG repeats and good response to endocrine
therapy was also found, but the mechanism and clinical relevance
are unclear. Since CAG repeat length correlates with age at onset
of prostate cancer, selection of patients with early onset disease is
a potential confounder in case–control studies of CAG repeat
length and prostate cancer risk. If mainly early onset cases are
included, the general risk of prostate cancer for men with short
CAG repeats is over-estimated if the effect of age at diagnosis is
not adjusted for. Thus, the present knowledge about how CAG
repeat length in the AR gene is related to prostate cancer risk and
biology is still very limited.
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